Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00520091
Other study ID # LCCC 0203
Secondary ID CDR0000561610
Status Completed
Phase Phase 2
First received August 21, 2007
Last updated May 16, 2012
Start date March 2005
Est. completion date September 2010

Study information

Verified date May 2012
Source UNC Lineberger Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority United States: Federal GovernmentUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy and radiation therapy together with celecoxib may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving irinotecan and cisplatin together with radiation therapy with or without celecoxib works in treating patients with stage II, stage III, or stage IV esophageal cancer.


Description:

OBJECTIVES:

Primary

- To measure the rates of cellular apoptosis and proliferation at baseline and during chemoradiotherapy with and without celecoxib using biopsy samples from patients with stage II, III, or IV esophageal cancer.

- To determine if an acceptable rate of pathologic complete remission can be achieved in a subset of patients with potentially resectable esophageal cancer.

Secondary

- To assess the safety of the addition of daily celecoxib to chemoradiotherapy.

- To estimate the median overall survival in a subset of patients with resectable disease.

- To quantitate expression of cyclooxygenase (COX)-2 and formation of prostaglandin E2 (PGE2) in patients with esophageal cancer.

- To assess the ability of celecoxib to decrease formation of PGE2 in tumor tissue by measuring pre- and post-treatment tumor concentrations of PGE2.

- To quantitate downstream effects of inhibition of COX-2 function in the setting of treatment with chemotherapy.

- To measure the radiographic response rate in patients with unresectable esophageal cancer.

OUTLINE: This is a multicenter study. Patients are sequentially enrolled into 1 of 2 treatment groups.

- Group 1: Patients receive cisplatin IV over 1 hour and irinotecan hydrochloride IV over 90 minutes on days 1, 8, 22, 29, 43, 50, 64, and 71. Patients also undergo radiotherapy once daily 5 days a week for 5 weeks beginning on day 43.

- Group 2: Patients receive chemoradiotherapy as in group 1. Patients also receive oral celecoxib twice daily beginning 3 days before the initiation of chemotherapy and continuing until the completion of chemoradiotherapy.

In both groups, patients with potentially resectable disease undergo surgery no more than 12 weeks after completion of chemoradiotherapy.

Endoscopic tumor biopsy specimens are collected at baseline and on day 3 of radiotherapy. Samples are analyzed for cyclooxygenase (COX)-2 gene and protein expression; PGE2 secretion; apoptotic activity; caspase-3 activation; cytochrome c translocation; VEGF mRNA quantitation; and cellular proliferation. Laboratory techniques used include RT-PCR, IHC, enzyme immunoassay, TUNEL assay, colorimetric assay, and northern blotting.

After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 34 patients (8-10 in group 1 and 24 in group 2) will be accrued for this study.


Other known NCT identifiers
  • NCT00280124

Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date September 2010
Est. primary completion date November 2006
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Biopsy proven squamous cell carcinoma or adenocarcinoma of the esophagus

- Lesions including the gastroesophageal junction allowed provided the tumor involves less than 2 cm of gastric cardia

- Meets 1 of the following criteria:

- Clinical stage II, III, or IV disease AND planning to receive chemoradiotherapy either for preoperative or palliative indications (group 1)

- Suitable candidate for bimodality (palliative intent) or trimodality (curative intent) therapy

- Clinical stage II or III disease AND candidate to receive chemoradiotherapy for preoperative indication followed by planned esophagectomy or esophagogastrectomy (group 2)

- Suitable candidate for trimodality (curative intent) therapy

- No tracheoesophageal fistula on bronchoscopy

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Life expectancy > 3 months (group 1)

- Not pregnant

- Adequate nutrition

- WBC = 4,000/µL

- ANC = 1,500/µL

- Platelet count = 100,000/µL

- Serum creatinine = 1.5 mg/dL

- Bilirubin = 1.5 mg/dL

- No other prior or concurrent malignancy other than curatively treated carcinoma in situ of the cervix; localized prostate cancer that was previously treated with local therapy more than 2 years ago with a PSA of less than 4 ng/mL; basal cell carcinoma of the skin; or superficial transitional cell carcinoma of the bladder

- Patients who have had a prior malignancy are eligible if they have been free of disease for = 5 years

- No serious medical or psychiatric illnesses that would preclude giving informed consent or otherwise limit survival to less than 2 years

- No history of known NSAID-induced gastrointestinal bleeding

- No current peptic ulcer disease

- No active coronary artery disease

- No myocardial infarction or cerebrovascular accident within the past 3 months

- No history of refractory congestive heart failure or cardiomyopathy

PRIOR CONCURRENT THERAPY:

- More than 1 week since prior major surgery (group 1)

- More than 2 weeks since prior major surgery (group 2)

- No prior chemotherapy or radiotherapy

- More than 30 days since prior cyclooxygenase-2 inhibitors (selective or non-selective), including, but not limited to, any of the following:

- Acetylsalicylic acid (aspirin)

- Piroxicam

- Diclofenac

- Meloxicam

- Indomethacin

- Fenoprofen

- Sulindac

- Flurbiprofen

- Tolmetin

- Ibuprofen

- Celecoxib

- Ketoprofen

- Rofecoxib

- Ketoprofen ER

- Valdecoxib

- Naproxen

- Meclofenamate

- Oxaprozin

- Mefenamic acid

- Etodolac

- Nabumetone

- Ketorolac

- No concurrent seizure medications

- No concurrent amifostine or other such agents

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
CPT- 11
65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
Cisplatin
Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
Celecoxib
400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin
Radiation:
Radiation
4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
Procedure:
Surgery
Surgery will occur prior to chemoradiation therapy for those patients with resectable disease

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
UNC Lineberger Comprehensive Cancer Center National Cancer Institute (NCI)

Outcome

Type Measure Description Time frame Safety issue
Primary Rates of cellular apoptosis and proliferation Measure the rates of cellular apoptotis and proliferation in esophageal cancers from biopsy samples pre-study and during chemoradiation with and without celecoxib therapy 5 weeks Yes
Primary Rate of pathologic complete remission in patients with resectable disease To determine if an acceptable rate of pathologic complete remissions can be achieved in a cohort of patients with potentially resectable esophageal carcinoma 4 years No
Secondary Number of subjects experiencing adverse events Adverse events/toxicity will graded per the CTCAE criteria 30 days post radiation Yes
Secondary Median overall survival of patients with resectable disease Follow up for survival will occur at 3 month intervals during the first two years, then every 6 months during years 3 and 4. 4 years No
Secondary Formation of prostaglandin E2 (PGE2) in tumor tissue The ability of celecoxib to decrease formation of prostaglandin E2 (PGE2) in tumor tissue will be analyzed using a Wilcoxon signed rank test on the difference (log scale) of the pre- and post-treatment tumor concentrations of PGE2 12 weeks No
Secondary Downstream effects of inhibition of cyclooxygenase 2 function A difference in location of the mRNA expression of the two cohorts will be tested for using the Wilcoxon rank sum test. A difference in the immunohistochemistry staining of the two cohorts will be tested for using polytomous logistic regression 12 weeks No
Secondary Response Rate Radiographic repsonse will be measured using RECIST critera in patients with unresectable esophageal cancer. 4 years No
See also
  Status Clinical Trial Phase
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
Not yet recruiting NCT05542680 - Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer N/A
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Completed NCT00003864 - Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus Phase 2
Recruiting NCT05491616 - Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Completed NCT00400114 - Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT04615806 - The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy N/A
Active, not recruiting NCT04566367 - Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer N/A
Active, not recruiting NCT03962179 - Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent) N/A
Terminated NCT01446874 - Prevention of Post-operative Pneumonia (POPP) Phase 2/Phase 3
Completed NCT03468634 - Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy N/A
Active, not recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Recruiting NCT02544737 - Apatinib for Metastatic Esophageal Cancer. Phase 2